Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or over~* Histological diagnosis of recurrent or metastatic gastric cancer~* Immunohistochemistry (IHC 0 or 1+) or FISH negative (if IHQ 2+) for HER2 on tissue biopsy, according to institutional routine~* Candidates to initiate first-line palliative treatment; Previous adjuvant treatment is allowed since its termination occurred at least 12 months ago~* ECOG performance range 0 to 2~* Informed consent form signed by patient or legal representative~Exclusion Criteria:~* Patients already on or previously using anti-HER2 therapy~* Left ventricular ejection fraction (LVEF) \<55% baseline, as already evaluated in the gastric cancer routine~* Pregnant or lactating women~* Patients participating in other experimental drug protocols~* Patients who received previous palliative chemotherapy~* Another synchronic neoplasia requiring systemic treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interventional (Type: EXPERIMENTAL): Use of trastuzumab combination chemotherapy in patients with relapsed or metastatic gastric cancer with expression HER2 negative in the tumor tissue but positive in CTC.

Based on this trial design, predict the completion outcome and termination type (if applicable).